Meningococcal meningitis in two patients with primary antibody deficiency treated with replacement intravenous immunoglobulin

S. Lear, E. Eren, J. Findlow, Raymond Borrow, D. Webster, S. Jolles*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

The current treatment of primary antibody deficiency (PAD) is the early recognition of the condition and replacement immune-globulin combined with prompt treatment of infections and complications. The route of administration (intravenous or subcutaneous), dose and frequency of administration of immunoglobulin still vary between centres and countries. Most infections in patients with PAD are reduced but not entirely prevented by replacement immunoglobulin, with sinopulmonary infections accounting for the bulk of the remainder. Although there have been reports of meningitis in patients with PAD before replacement treatment, we describe the first two cases of bacterial meningitis (group B Neisseria meningitidis) on adequate immunoglobulin replacement and discuss the involvement of potential cofactors.

Original languageEnglish
Pages (from-to)1191-1193
Number of pages3
JournalJournal of Clinical Pathology
Volume59
Issue number11
DOIs
Publication statusPublished - Nov 2006

Fingerprint

Dive into the research topics of 'Meningococcal meningitis in two patients with primary antibody deficiency treated with replacement intravenous immunoglobulin'. Together they form a unique fingerprint.

Cite this